Zymergen Investors Can't Beat Suit Over Pre-IPO Statements <https://www.law360.com/capitalmarkets/articles/1870187?nl_pk=abe82add-2a33-4388-8f7e-63d76e8f5534&utm_source=newsletter&utm_medium=email&utm_campaign=capitalmarkets&utm_content=2024-08-16&read_main=1&nlsidx=0&nlaidx=2> By Sydney Price Three of the largest investors of biotechnology company Zymergen cannot escape a suit accusing them of misleading shareholders ahead of the company's initial public offering by approving misstatements about the company's commercial product pipeline. Order attached | Read full article » <https://www.law360.com/capitalmarkets/articles/1870187?nl_pk=abe82add-2a33-4388-8f7e-63d76e8f5534&utm_source=newsletter&utm_medium=email&utm_campaign=capitalmarkets&utm_content=2024-08-16&read_more=1&nlsidx=0&nlaidx=2> | Save to favorites » <https://www.law360.com/capitalmarkets/articles/1870187?nl_pk=abe82add-2a33-4388-8f7e-63d76e8f5534&utm_source=newsletter&utm_medium=email&utm_campaign=capitalmarkets&utm_content=2024-08-16&read_later=1&nlsidx=0&nlaidx=2>